Tectonic Therapeutic, Inc.
TECX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $41 | $37 | $26 | $11 |
| G&A Expenses | $17 | $8 | $7 | $5 |
| SG&A Expenses | $17 | $8 | $7 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $58 | $45 | $33 | $16 |
| Operating Income | -$58 | -$45 | -$33 | -$16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $2 | $1 | $7 |
| Pre-Tax Income | -$58 | -$43 | -$32 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$58 | -$43 | -$32 | -$9 |
| % Margin | – | – | – | – |
| EPS | -3.93 | -11.59 | -29.05 | -33.36 |
| % Growth | 66.1% | 60.1% | 12.9% | – |
| EPS Diluted | -3.93 | -11.53 | -29.05 | -33.36 |
| Weighted Avg Shares Out | 15 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 15 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $0 |
| EBITDA | -$56 | -$41 | -$31 | -$8 |
| % Margin | – | – | – | – |